secwatch / observer

8-K filed November 10, 2022, 6:59 PM ET ticker ANEB CIK 0001815974

earnings confidence high sentiment neutral materiality 0.60

Anebulo Pharma Q1 FY2023 net loss $2.6M ($0.11/sh); positive ANEB-001 Phase 2 data

Anebulo Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.11

Net loss $2.6M vs $1.6M YoY; diluted EPS ($0.11) vs ($0.07).
Cash $19.2M at Sept 30, 2022; cash burn $2.0M in quarter.
Positive interim data for ANEB-001 from Phase 2 Part B announced.
Closed $6.6M private placement financing in September 2022.
Appointed Nat Calloway, Ph.D. to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Anebulo Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $(0.11) per share, EPS $(0.11) per share.

Period: the three months ended September 30, 2022
Net income: $(0.11) per share
EPS: $(0.11) per share
Result: reported results

Exact text from the filing

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

View on SEC.gov

Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.